These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 29155436

  • 1. Enzyme replacement therapy for infantile-onset Pompe disease.
    Chen M, Zhang L, Quan S.
    Cochrane Database Syst Rev; 2017 Nov 20; 11(11):CD011539. PubMed ID: 29155436
    [Abstract] [Full Text] [Related]

  • 2. Enzyme replacement therapy for late-onset Pompe disease.
    Dalmia S, Sharma R, Ramaswami U, Hughes D, Jahnke N, Cole D, Smith S, Remmington T.
    Cochrane Database Syst Rev; 2023 Dec 12; 12(12):CD012993. PubMed ID: 38084761
    [Abstract] [Full Text] [Related]

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K, Williams J, Qi YP, Gutman J, Yeung L, Mai C, Finkelstain J, Mehta S, Pons-Duran C, Menéndez C, Moraleda C, Rogers L, Daniels K, Green P.
    Cochrane Database Syst Rev; 2022 Feb 01; 2(2022):. PubMed ID: 36321557
    [Abstract] [Full Text] [Related]

  • 4. Enzyme replacement therapy for Anderson-Fabry disease.
    El Dib R, Gomaa H, Carvalho RP, Camargo SE, Bazan R, Barretti P, Barreto FC.
    Cochrane Database Syst Rev; 2016 Jul 25; 7(7):CD006663. PubMed ID: 27454104
    [Abstract] [Full Text] [Related]

  • 5. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial.
    Diaz-Manera J, Kishnani PS, Kushlaf H, Ladha S, Mozaffar T, Straub V, Toscano A, van der Ploeg AT, Berger KI, Clemens PR, Chien YH, Day JW, Illarioshkin S, Roberts M, Attarian S, Borges JL, Bouhour F, Choi YC, Erdem-Ozdamar S, Goker-Alpan O, Kostera-Pruszczyk A, Haack KA, Hug C, Huynh-Ba O, Johnson J, Thibault N, Zhou T, Dimachkie MM, Schoser B, COMET Investigator Group.
    Lancet Neurol; 2021 Dec 25; 20(12):1012-1026. PubMed ID: 34800399
    [Abstract] [Full Text] [Related]

  • 6. Enzyme replacement and substrate reduction therapy for Gaucher disease.
    Shemesh E, Deroma L, Bembi B, Deegan P, Hollak C, Weinreb NJ, Cox TM.
    Cochrane Database Syst Rev; 2015 Mar 27; 2015(3):CD010324. PubMed ID: 25812601
    [Abstract] [Full Text] [Related]

  • 7. Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial.
    Schoser B, Roberts M, Byrne BJ, Sitaraman S, Jiang H, Laforêt P, Toscano A, Castelli J, Díaz-Manera J, Goldman M, van der Ploeg AT, Bratkovic D, Kuchipudi S, Mozaffar T, Kishnani PS, PROPEL Study Group.
    Lancet Neurol; 2021 Dec 27; 20(12):1027-1037. PubMed ID: 34800400
    [Abstract] [Full Text] [Related]

  • 8. Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease.
    Case LE, Bjartmar C, Morgan C, Casey R, Charrow J, Clancy JP, Dasouki M, DeArmey S, Nedd K, Nevins M, Peters H, Phillips D, Spigelman Z, Tifft C, Kishnani PS.
    Neuromuscul Disord; 2015 Apr 27; 25(4):321-32. PubMed ID: 25617983
    [Abstract] [Full Text] [Related]

  • 9. Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia.
    Ng SM, Stepien KM, Krishan A.
    Cochrane Database Syst Rev; 2020 Mar 19; 3(3):CD012517. PubMed ID: 32190901
    [Abstract] [Full Text] [Related]

  • 10. Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI.
    Brunelli MJ, Atallah ÁN, da Silva EM.
    Cochrane Database Syst Rev; 2016 Mar 04; 3():CD009806. PubMed ID: 26943923
    [Abstract] [Full Text] [Related]

  • 11. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
    da Silva EM, Strufaldi MW, Andriolo RB, Silva LA.
    Cochrane Database Syst Rev; 2016 Feb 05; 2(2):CD008185. PubMed ID: 26845288
    [Abstract] [Full Text] [Related]

  • 12. Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascending dose study.
    Pena LDM, Barohn RJ, Byrne BJ, Desnuelle C, Goker-Alpan O, Ladha S, Laforêt P, Mengel KE, Pestronk A, Pouget J, Schoser B, Straub V, Trivedi J, Van Damme P, Vissing J, Young P, Kacena K, Shafi R, Thurberg BL, Culm-Merdek K, van der Ploeg AT, NEO1 Investigator Group.
    Neuromuscul Disord; 2019 Mar 05; 29(3):167-186. PubMed ID: 30770310
    [Abstract] [Full Text] [Related]

  • 13. Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI.
    Brunelli MJ, Atallah ÁN, da Silva EM.
    Cochrane Database Syst Rev; 2021 Sep 17; 9(9):CD009806. PubMed ID: 34533215
    [Abstract] [Full Text] [Related]

  • 14. Optimizing treatment outcomes: immune tolerance induction in Pompe disease patients undergoing enzyme replacement therapy.
    Chen HA, Hsu RH, Fang CY, Desai AK, Lee NC, Hwu WL, Tsai FJ, Kishnani PS, Chien YH.
    Front Immunol; 2024 Sep 17; 15():1336599. PubMed ID: 38715621
    [Abstract] [Full Text] [Related]

  • 15. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
    da Silva EM, Strufaldi MW, Andriolo RB, Silva LA.
    Cochrane Database Syst Rev; 2014 Jan 08; (1):CD008185. PubMed ID: 24399699
    [Abstract] [Full Text] [Related]

  • 16. Safety and efficacy of avalglucosidase alfa in individuals with infantile-onset Pompe disease enrolled in the phase 2, open-label Mini-COMET study: The 6-month primary analysis report.
    Kishnani PS, Kronn D, Brassier A, Broomfield A, Davison J, Hahn SH, Kumada S, Labarthe F, Ohki H, Pichard S, Prakalapakorn SG, Haack KA, Kittner B, Meng X, Sparks S, Wilson C, Zaher A, Chien YH, Mini-COMET Investigators.
    Genet Med; 2023 Feb 08; 25(2):100328. PubMed ID: 36542086
    [Abstract] [Full Text] [Related]

  • 17. Dornase alfa for cystic fibrosis.
    Yang C, Montgomery M.
    Cochrane Database Syst Rev; 2021 Mar 18; 3(3):CD001127. PubMed ID: 33735508
    [Abstract] [Full Text] [Related]

  • 18. Dornase alfa for cystic fibrosis.
    Yang C, Montgomery M.
    Cochrane Database Syst Rev; 2018 Sep 06; 9(9):CD001127. PubMed ID: 30187450
    [Abstract] [Full Text] [Related]

  • 19. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
    da Silva EM, Strufaldi MW, Andriolo RB, Silva LA.
    Cochrane Database Syst Rev; 2011 Nov 09; (11):CD008185. PubMed ID: 22071845
    [Abstract] [Full Text] [Related]

  • 20. Alglucosidase alfa: new drug. Pompe disease: a short-term benefit.
    Prescrire Int; 2007 Dec 09; 16(92):240-1. PubMed ID: 18092404
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.